查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1481780

全球肿瘤学伴随诊断测试市场研究报告 - 2024 年至 2032 年行业分析、规模、份额、成长、趋势和预测

Global Companion Diagnostic Tests in Oncology Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
出版日期: | 出版商: Value Market Research | 英文 281 Pages | 商品交期: 最快1-2个工作天内

价格

预计到 2032 年，全球肿瘤市场伴随诊断测试的市场规模将从 2023 年的 58.9 亿美元达到近 139.9 亿美元，2024-2032 年研究期间复合年增长率为 10.09%。

肿瘤学中的伴随诊断测试旨在识别与患者的癌症诊断或预后相关的特定生物标记或分子标靶。这些测试与标靶癌症疗法一起使用，以个性化治疗决策、预测治疗反应并监测疾病进展。这些测试分析生物样本，如组织活检、血液样本或循环肿瘤 DNA，以检测基因突变、基因扩增、蛋白质表现量或其他指示癌症亚型、分期或治疗反应的分子变化。透过提供有关患者肿瘤生物学的可行信息，伴随诊断测试使肿瘤学家能够在精准肿瘤学实践中製定治疗策略、优化治疗选择并改善患者的治疗效果。

市场动态

全球癌症的流行，加上分子生物学和基因组学的进步，正在推动用于个人化癌症治疗的伴随诊断测试的开发和采用。此外，对精准医疗和基于价值的医疗保健的日益重视推动了对辅助诊断测试的需求，这些测试有助于优化治疗结果、最大限度地减少不良反应并降低医疗成本。此外，监管机构简化药物审批流程和鼓励标靶治疗开发的措施正在推动对伴随诊断测试开发和商业化的投资。此外，製药公司、诊断实验室和研究机构之间的合作和伙伴关係推动创新并加速针对新兴生物标记和治疗标靶的伴随诊断测试的开发。此外，液体活检和新一代定序 (NGS) 技术的日益普及正在扩大伴随诊断测试的范围和能力，从而能够对肿瘤进行非侵入性和全面的分析，以实现精准肿瘤学应用。然而，不断变化的监管环境和报销挑战可能会对未来几年肿瘤学市场成长的伴随诊断测试提出挑战。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具还对全球肿瘤学伴随诊断测试市场的每个细分市场进行了包容性评估。肿瘤学产业伴随诊断测试的成长和趋势为这项研究提供了整体方法。

市场区隔

肿瘤学市场报告中的伴随诊断测试的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助策略师确定相应产品或服务的目标人群以及即将到来的机会。

依检测技术

  • 蛋白质检测（免疫组织化学）
  • DNA 检测（聚合酶炼式反应 (Pcr)、新一代定序 (NGs)、原位杂交）
  • 其他的

透过生物标誌物

  • 表皮生长因子受体
  • 克拉斯
  • HER2
  • 布拉夫V600E
  • 其他的

按癌症类型

  • 乳癌
  • 肺癌
  • 大肠直肠癌
  • 肝癌
  • 黑色素瘤
  • 其他的

按最终用户

  • 医院
  • 专科诊所
  • 诊断实验室
  • 其他的

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲肿瘤学伴随诊断测试市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。肿瘤伴随诊断测试市场的主要参与者包括 Abbott、F. Hoffmann-LA Roche AG、Genomic Health, Inc.、Qiagen、Agilent Technologies, Inc.、Agendia NV、bioMerieux SA、Illumina, Inc.、Siemens Healthineers、赛默飞世尔科技公司、BioGenex。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

目录

第一章：前言

  • 报告说明
    • 客观的
    • 目标受众
    • 独特的销售主张 (USP) 和产品
  • 研究范围
  • 研究方法论
    • 市场研究过程
    • 市场研究方法论

第 2 章：执行摘要

  • 市集亮点
  • 全球市场概况

第 3 章：肿瘤学中的伴随诊断测试 - 产业分析

  • 简介 - 市场动态
  • 市场驱动因素
  • 市场限制
  • 机会
  • 产业动态
  • 波特五力分析
  • 市场吸引力分析
    • 透过检测技术进行市场吸引力分析
    • 生物标誌物的市场吸引力分析
    • 按癌症类型分類的市场吸引力分析
    • 最终用户的市场吸引力分析
    • 市场吸引力分析：按地区

第 4 章：价值链分析

  • 价值链分析
  • 原料分析
    • 原料清单
    • 原料厂商清单
    • 主要原物料价格走势
  • 潜在买家名单
  • 行销管道
    • 直效行销
    • 间接行销
    • 行销通路发展趋势

第 5 章：肿瘤学市场分析中的全球伴随诊断测试：按检测技术

  • 依检测技术概述
  • 历史和预测数据
  • 检测技术分析
  • 蛋白质检测（免疫组织化学）
  • DNA 检测（聚合酶炼式反应 (PCR)、新一代定序 (NGS)、原位杂交）
  • 其他的

第 6 章：肿瘤学市场分析中的全球伴随诊断测试：按生物标记

  • 生物标誌物概述
  • 历史和预测数据
  • 生物标记分析
  • 表皮生长因子受体
  • 克拉斯
  • HER2
  • 布拉夫V600E
  • 其他的

第 7 章：肿瘤学市场分析中的全球伴随诊断测试：按癌症类型

  • 按癌症类型概述
  • 历史和预测数据
  • 按癌症类型分析
  • 乳癌
  • 肺癌
  • 大肠直肠癌
  • 肝癌
  • 黑色素瘤
  • 其他的

第 8 章：肿瘤学市场分析中的全球伴随诊断测试：按最终用户

  • 最终用户概述
  • 历史和预测数据
  • 最终用户分析
  • 医院
  • 专科诊所
  • 诊断实验室
  • 其他的

第 9 章：肿瘤学市场分析中的全球伴随诊断测试：按地理位置

  • 区域展望
  • 介绍
  • 北美销售分析
    • 概览、历史与预测资料销售分析
    • 北美按细分市场销售分析
    • 北美按国家销售分析
    • 美国销售分析
    • 加拿大销售分析
    • 墨西哥销售分析
  • 欧洲销售分析
    • 概览、历史与预测资料销售分析
    • 欧洲按细分市场销售分析
    • 欧洲按国家销售分析
    • 英国销售分析
    • 法国销售分析
    • 德国销售分析
    • 义大利销售分析
    • 俄罗斯销售分析
    • 欧洲其他地区销售分析
  • 亚太地区销售分析
    • 概览、历史与预测资料销售分析
    • 亚太地区按细分市场销售分析
    • 亚太地区按国家销售分析
    • 中国销售分析
    • 印度销售分析
    • 日本销售分析
    • 韩国销售分析
    • 澳洲销售分析
    • 东南亚销售分析
    • 亚太地区其他地区销售分析
  • 拉丁美洲销售分析
    • 概览、历史与预测资料销售分析
    • 拉丁美洲按细分市场销售分析
    • 拉丁美洲按国家销售分析
    • 巴西销售分析
    • 阿根廷销售分析
    • 秘鲁销售分析
    • 智利销售分析
    • 拉丁美洲其他地区销售分析
  • 中东和非洲销售分析
    • 概览、历史与预测资料销售分析
    • 中东和非洲按细分市场销售分析
    • 中东和非洲按国家销售分析
    • 沙乌地阿拉伯销售分析
    • 阿联酋销售分析
    • 以色列销售分析
    • 南非销售分析
    • 中东其他地区和非洲销售分析

第 10 章：肿瘤公司伴随诊断测试的竞争格局

  • 肿瘤学市场竞争中的伴随诊断测试
  • 伙伴关係/协作/协议
  • 併购
  • 新产品发布
  • 其他发展

第 11 章：公司简介

  • 顶级公司市占率分析
  • 市场集中度
  • Abbott
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • F. Hoffmann-LA Roche AG
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Genomic Health Inc.
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • QIAGEN
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Agilent Technologies Inc.
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Agendia NV
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • BioMeRieux SA
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Illumina Inc.
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Siemens Healthineers
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Thermo Fisher Scientific Inc.
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • BioGenex.
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展

註 - 在公司概况中，财务详细资料和最新进展视情况而定，或对私人公司而言可能不包括在内

Product Code: VMR112114403

The global demand for Companion Diagnostic Tests in Oncology Market is presumed to reach the market size of nearly USD 13.99 Billion by 2032 from USD 5.89 Billion in 2023 with a CAGR of 10.09% under the study period 2024 - 2032.

Companion diagnostic tests in oncology are designed to identify specific biomarkers or molecular targets associated with a patient's cancer diagnosis or prognosis. These tests are used with targeted cancer therapies to personalize treatment decisions, predict treatment response, and monitor disease progression. These tests analyze biological samples such as tissue biopsies, blood samples, or circulating tumor DNA to detect genetic mutations, gene amplifications, protein expression levels, or other molecular alterations indicative of cancer subtype, stage, or treatment response. By providing actionable information about a patient's tumor biology, companion diagnostic tests enable oncologists to tailor treatment strategies, optimize therapy selection, and improve patient outcomes in precision oncology practice.

MARKET DYNAMICS

The spurring prevalence of cancer worldwide, coupled with advancements in molecular biology and genomics, is driving the development and adoption of companion diagnostic tests for personalized cancer treatment. Additionally, the escalating emphasis on precision medicine and value-based healthcare drives demand for companion diagnostic tests that help optimize treatment outcomes, minimize adverse effects, and reduce healthcare costs. Moreover, regulatory agencies' initiatives to streamline drug approval processes and encourage the development of targeted therapies are driving investment in companion diagnostic test development and commercialization. Furthermore, collaborations and partnerships between pharmaceutical companies, diagnostic laboratories, and research institutions drive innovation and accelerate the development of companion diagnostic tests for emerging biomarkers and therapeutic targets. Additionally, the growing adoption of liquid biopsy and next-generation sequencing (NGS) technologies is expanding the scope and capabilities of companion diagnostic tests, enabling non-invasive and comprehensive profiling of tumors for precision oncology applications. However, the evolving regulatory landscape and reimbursement challenges may challenge the companion diagnostic tests in oncology market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of companion diagnostic tests in oncology. The growth and trends of companion diagnostic tests in oncology industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the companion diagnostic tests in oncology market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Detection Technique

  • Protein Detection (Immunohistochemistry)
  • DNA Detection (Polymerase Chain Reaction (Pcr), Next-Generation Sequencing (Ngs), In Situ Hybridization)
  • Others

By Biomarker

  • EGFR
  • KRAS
  • HER2
  • BRAF V600E
  • Others

By Cancer Type

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Liver Cancer
  • Melanoma
  • Others

By End-User

  • Hospitals
  • Specialty Clinics
  • Diagnostic Labs
  • Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Companion Diagnostic Tests in Oncology market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Companion Diagnostic Tests in Oncology market include Abbott, F. Hoffmann-LA Roche AG, Genomic Health, Inc., Qiagen, Agilent Technologies, Inc., Agendia N.V., bioMerieux SA, Illumina, Inc., Siemens Healthineers, Thermo Fisher Scientific Inc., BioGenex. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. COMPANION DIAGNOSTIC TESTS IN ONCOLOGY - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Detection Technique
    • 3.7.2 Market Attractiveness Analysis By Biomarker
    • 3.7.3 Market Attractiveness Analysis By Cancer Type
    • 3.7.4 Market Attractiveness Analysis By End-user
    • 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL COMPANION DIAGNOSTIC TESTS IN ONCOLOGY MARKET ANALYSIS BY DETECTION TECHNIQUE

  • 5.1. Overview By Detection Technique
  • 5.2. Historical and Forecast Data
  • 5.3. Analysis By Detection Technique
  • 5.4. Protein Detection (Immunohistochemistry) Historic and Forecast Sales By Regions
  • 5.5. DNA Detection (Polymerase Chain Reaction (PCR), Next-generation Sequencing (NGS), In Situ Hybridization) Historic and Forecast Sales By Regions
  • 5.6. Others Historic and Forecast Sales By Regions

6. GLOBAL COMPANION DIAGNOSTIC TESTS IN ONCOLOGY MARKET ANALYSIS BY BIOMARKER

  • 6.1. Overview By Biomarker
  • 6.2. Historical and Forecast Data
  • 6.3. Analysis By Biomarker
  • 6.4. EGFR Historic and Forecast Sales By Regions
  • 6.5. KRAS Historic and Forecast Sales By Regions
  • 6.6. HER2 Historic and Forecast Sales By Regions
  • 6.7. BRAF V600E Historic and Forecast Sales By Regions
  • 6.8. Others Historic and Forecast Sales By Regions

7. GLOBAL COMPANION DIAGNOSTIC TESTS IN ONCOLOGY MARKET ANALYSIS BY CANCER TYPE

  • 7.1. Overview By Cancer Type
  • 7.2. Historical and Forecast Data
  • 7.3. Analysis By Cancer Type
  • 7.4. Breast Cancer Historic and Forecast Sales By Regions
  • 7.5. Lung Cancer Historic and Forecast Sales By Regions
  • 7.6. Colorectal Cancer Historic and Forecast Sales By Regions
  • 7.7. Liver Cancer Historic and Forecast Sales By Regions
  • 7.8. Melanoma Historic and Forecast Sales By Regions
  • 7.9. Others Historic and Forecast Sales By Regions

8. GLOBAL COMPANION DIAGNOSTIC TESTS IN ONCOLOGY MARKET ANALYSIS BY END-USER

  • 8.1. Overview By End-user
  • 8.2. Historical and Forecast Data
  • 8.3. Analysis By End-user
  • 8.4. Hospitals Historic and Forecast Sales By Regions
  • 8.5. Specialty Clinics Historic and Forecast Sales By Regions
  • 8.6. Diagnostic Labs Historic and Forecast Sales By Regions
  • 8.7. Others Historic and Forecast Sales By Regions

9. GLOBAL COMPANION DIAGNOSTIC TESTS IN ONCOLOGY MARKET ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook
  • 9.2. Introduction
  • 9.3. North America Sales Analysis
    • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.3.2 North America By Segment Sales Analysis
    • 9.3.3 North America By Country Sales Analysis
    • 9.3.4 United States Sales Analysis
    • 9.3.5 Canada Sales Analysis
    • 9.3.6 Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.4.2 Europe By Segment Sales Analysis
    • 9.4.3 Europe By Country Sales Analysis
    • 9.4.4 United Kingdom Sales Analysis
    • 9.4.5 France Sales Analysis
    • 9.4.6 Germany Sales Analysis
    • 9.4.7 Italy Sales Analysis
    • 9.4.8 Russia Sales Analysis
    • 9.4.9 Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.5.2 Asia Pacific By Segment Sales Analysis
    • 9.5.3 Asia Pacific By Country Sales Analysis
    • 9.5.4 China Sales Analysis
    • 9.5.5 India Sales Analysis
    • 9.5.6 Japan Sales Analysis
    • 9.5.7 South Korea Sales Analysis
    • 9.5.8 Australia Sales Analysis
    • 9.5.9 South East Asia Sales Analysis
    • 9.5.10 Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.6.2 Latin America By Segment Sales Analysis
    • 9.6.3 Latin America By Country Sales Analysis
    • 9.6.4 Brazil Sales Analysis
    • 9.6.5 Argentina Sales Analysis
    • 9.6.6 Peru Sales Analysis
    • 9.6.7 Chile Sales Analysis
    • 9.6.8 Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.7.2 Middle East & Africa By Segment Sales Analysis
    • 9.7.3 Middle East & Africa By Country Sales Analysis
    • 9.7.4 Saudi Arabia Sales Analysis
    • 9.7.5 UAE Sales Analysis
    • 9.7.6 Israel Sales Analysis
    • 9.7.7 South Africa Sales Analysis
    • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE COMPANION DIAGNOSTIC TESTS IN ONCOLOGY COMPANIES

  • 10.1. Companion Diagnostic Tests in Oncology Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11. COMPANY PROFILES OF COMPANION DIAGNOSTIC TESTS IN ONCOLOGY INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. Abbott
    • 11.3.1 Company Overview
    • 11.3.2 Company Revenue
    • 11.3.3 Products
    • 11.3.4 Recent Developments
  • 11.4. F. Hoffmann-LA Roche AG
    • 11.4.1 Company Overview
    • 11.4.2 Company Revenue
    • 11.4.3 Products
    • 11.4.4 Recent Developments
  • 11.5. Genomic Health Inc.
    • 11.5.1 Company Overview
    • 11.5.2 Company Revenue
    • 11.5.3 Products
    • 11.5.4 Recent Developments
  • 11.6. QIAGEN
    • 11.6.1 Company Overview
    • 11.6.2 Company Revenue
    • 11.6.3 Products
    • 11.6.4 Recent Developments
  • 11.7. Agilent Technologies Inc.
    • 11.7.1 Company Overview
    • 11.7.2 Company Revenue
    • 11.7.3 Products
    • 11.7.4 Recent Developments
  • 11.8. Agendia N.V.
    • 11.8.1 Company Overview
    • 11.8.2 Company Revenue
    • 11.8.3 Products
    • 11.8.4 Recent Developments
  • 11.9. BioMeRieux SA
    • 11.9.1 Company Overview
    • 11.9.2 Company Revenue
    • 11.9.3 Products
    • 11.9.4 Recent Developments
  • 11.10. Illumina Inc.
    • 11.10.1 Company Overview
    • 11.10.2 Company Revenue
    • 11.10.3 Products
    • 11.10.4 Recent Developments
  • 11.11. Siemens Healthineers
    • 11.11.1 Company Overview
    • 11.11.2 Company Revenue
    • 11.11.3 Products
    • 11.11.4 Recent Developments
  • 11.12. Thermo Fisher Scientific Inc.
    • 11.12.1 Company Overview
    • 11.12.2 Company Revenue
    • 11.12.3 Products
    • 11.12.4 Recent Developments
  • 11.13. BioGenex.
    • 11.13.1 Company Overview
    • 11.13.2 Company Revenue
    • 11.13.3 Products
    • 11.13.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Detection Technique (USD MN)
  • Protein Detection (Immunohistochemistry) Market Sales By Geography (USD MN)
  • DNA Detection (Polymerase Chain Reaction (PCR), Next-generation Sequencing (NGS), In Situ Hybridization) Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By Biomarker (USD MN)
  • EGFR Market Sales By Geography (USD MN)
  • KRAS Market Sales By Geography (USD MN)
  • HER2 Market Sales By Geography (USD MN)
  • BRAF V600E Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By Cancer Type (USD MN)
  • Breast Cancer Market Sales By Geography (USD MN)
  • Lung Cancer Market Sales By Geography (USD MN)
  • Colorectal Cancer Market Sales By Geography (USD MN)
  • Liver Cancer Market Sales By Geography (USD MN)
  • Melanoma Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By End-user (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Specialty Clinics Market Sales By Geography (USD MN)
  • Diagnostic Labs Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Companion Diagnostic Tests in Oncology Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Companion Diagnostic Tests in Oncology Report
  • Market Research Process
  • Market Research Methodology
  • Global Companion Diagnostic Tests in Oncology Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Detection Technique
  • Market Attractiveness Analysis By Biomarker
  • Market Attractiveness Analysis By Cancer Type
  • Market Attractiveness Analysis By End-user
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Detection Technique (USD MN)
  • Protein Detection (Immunohistochemistry) Market Sales By Geography (USD MN)
  • DNA Detection (Polymerase Chain Reaction (PCR), Next-generation Sequencing (NGS), In Situ Hybridization) Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By Biomarker (USD MN)
  • EGFR Market Sales By Geography (USD MN)
  • KRAS Market Sales By Geography (USD MN)
  • HER2 Market Sales By Geography (USD MN)
  • BRAF V600E Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By Cancer Type (USD MN)
  • Breast Cancer Market Sales By Geography (USD MN)
  • Lung Cancer Market Sales By Geography (USD MN)
  • Colorectal Cancer Market Sales By Geography (USD MN)
  • Liver Cancer Market Sales By Geography (USD MN)
  • Melanoma Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By End-user (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Specialty Clinics Market Sales By Geography (USD MN)
  • Diagnostic Labs Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.